Physician profile
Robert Charles Turner
NPI 1144372863
$7,171.82
in general payments reported to CMS, 2019-2025
34 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 85% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $754 · 2021: $1,167 · 2022: $1,088 · 2023: $1,492 · 2024: $1,130 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,339.74 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $682.62 | 2020-2023 | Spravato |
| Pfizer INC. | $452.68 | 2023-2025 | |
| Indivior INC. | $445.36 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $414.01 | 2020-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.02 | 2019-2025 | Xifaxan |
| Corium, LLC | $288.00 | 2022-2025 | Azstarys |
| Orexo US, INC. | $269.78 | 2019-2024 | Zubsolv |
| Alkermes, INC. | $249.77 | 2019-2024 | Vivitrol, Vivitrol |
| Supernus Pharmaceuticals, INC. | $215.60 | 2022-2024 | Qelbree, Qelbree |
| Corcept Therapeutics | $171.24 | 2019-2022 | |
| Allergan, INC. | $144.16 | 2020 | |
| Idorsia Pharmaceuticals US INC | $115.86 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $108.82 | 2020-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.49 | 2022-2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.09 | 2019-2025 | Wegovy |
| Mdd US Operations, LLC | $96.87 | 2019-2020 | |
| Tris Pharma INC | $77.22 | 2022-2023 | Dyanavel Xr |
| Eisai INC. | $74.09 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $70.55 | 2020-2023 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceuticals, INC. | $64.46 | 2021 | |
| Lilly USA, LLC | $63.04 | 2019-2024 | Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $45.30 | 2024-2025 | Voquezna |
| Shire North American Group INC | $35.54 | 2019 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Medline Industries LP | $31.43 | 2024 | |
| Sunovion Pharmaceuticals INC. | $29.83 | 2021 | |
| Braeburn INC. | $28.76 | 2023-2025 | Brixadi |
| Azurity Pharmaceuticals, INC. | $27.05 | 2023 | Adthyza |
| Noven Therapeutics, LLC | $17.54 | 2023 | Xelstrym |
| Optinose US, INC. | $16.12 | 2019 | |
| Amgen INC. | $14.65 | 2020 | |
| Lundbeck LLC | $12.88 | 2023 | Rexulti |
| Fidia Pharma USA INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.